140 related articles for article (PubMed ID: 34689489)
1. Impact of Muscle Mass Depletion on Surgical Outcomes in Patients with Primary High-grade Serous Ovarian Cancer Undergoing CRS and HIPEC.
Mercan U; Gulpinar B; Ersen O; Kosmaz K; Durhan A; Unal AE
J Coll Physicians Surg Pak; 2021 Nov; 31(11):1314-1319. PubMed ID: 34689489
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
3. Skeletal Muscle Depletion is Associated with Severe Postoperative Complications in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Cancer.
van Vugt JL; Braam HJ; van Oudheusden TR; Vestering A; Bollen TL; Wiezer MJ; de Hingh IH; van Ramshorst B; Boerma D
Ann Surg Oncol; 2015 Oct; 22(11):3625-31. PubMed ID: 25672564
[TBL] [Abstract][Full Text] [Related]
4. The impact of sarcopenia on morbidity and long-term survival among patients with peritoneal metastases of colorectal origin treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a 10-year longitudinal analysis of a single-center experience.
Agalar C; Sokmen S; Arslan C; Altay C; Basara I; Canda AE; Obuz F
Tech Coloproctol; 2020 Apr; 24(4):301-308. PubMed ID: 32080800
[TBL] [Abstract][Full Text] [Related]
5. Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer.
Chemama S; Bayar MA; Lanoy E; Ammari S; Stoclin A; Goéré D; Elias D; Raynard B; Antoun S
Ann Surg Oncol; 2016 Nov; 23(12):3891-3898. PubMed ID: 27352205
[TBL] [Abstract][Full Text] [Related]
6. High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy.
Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liu Z; Zheng Z; Chen H; Wang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X
BMC Cancer; 2021 Jan; 21(1):41. PubMed ID: 33413223
[TBL] [Abstract][Full Text] [Related]
7. Overall survival of pseudomyxoma peritonei and peritoneal mesothelioma patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be predicted by computed tomography quantified sarcopenia.
Galan A; Rousset P; Mercier F; Képénékian V; Valette PJ; Glehen O; Passot G
Eur J Surg Oncol; 2018 Nov; 44(11):1818-1823. PubMed ID: 30143249
[TBL] [Abstract][Full Text] [Related]
8. HIPEC plus EPIC paclitaxel for maximal perioperative treatments of advanced epithelial ovarian cancer. Long-term results of a pilot study.
Sugarbaker PH; Stuart OA
Surg Oncol; 2020 Dec; 35():441-446. PubMed ID: 33039850
[TBL] [Abstract][Full Text] [Related]
9. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
[TBL] [Abstract][Full Text] [Related]
10. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy.
Zhou S; Jiang Y; Liang J; Pei W; Zhou Z
World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125
[TBL] [Abstract][Full Text] [Related]
12. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer.
Cascales Campos P; Gil J; Parrilla P
Eur J Surg Oncol; 2014 Aug; 40(8):970-5. PubMed ID: 24035502
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
Ansaloni L; Agnoletti V; Amadori A; Catena F; Cavaliere D; Coccolini F; De Iaco P; Di Battista M; Framarini M; Gazzotti F; Ghermandi C; Kopf B; Saponara M; Tauceri F; Vallicelli C; Verdecchia GM; Pinna AD
Int J Gynecol Cancer; 2012 Jun; 22(5):778-85. PubMed ID: 22572845
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive surgery under aminolevulinic acid-mediated photodynamic diagnosis plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from ovarian cancer and primary peritoneal carcinoma: results of a phase I trial.
Liu Y; Endo Y; Fujita T; Ishibashi H; Nishioka T; Canbay E; Li Y; Ogura S; Yonemura Y
Ann Surg Oncol; 2014 Dec; 21(13):4256-62. PubMed ID: 25056850
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves the survival of gastric cancer patients with ovarian metastasis and peritoneal dissemination.
Wu XJ; Yuan P; Li ZY; Bu ZD; Zhang LH; Wu AW; Zong XL; Li SX; Shan F; Ji X; Ren H; Ji JF
Tumour Biol; 2013 Feb; 34(1):463-9. PubMed ID: 23108893
[TBL] [Abstract][Full Text] [Related]
16. A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion.
Downs-Canner S; Ding Y; Magge DR; Jones H; Ramalingam L; Zureikat A; Holtzman M; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2015 May; 22(5):1651-7. PubMed ID: 25348781
[TBL] [Abstract][Full Text] [Related]
17. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
[TBL] [Abstract][Full Text] [Related]
18. Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures.
Foster JM; Sleightholm R; Patel A; Shostrom V; Hall B; Neilsen B; Bartlett D; Smith L
JAMA Netw Open; 2019 Jan; 2(1):e186847. PubMed ID: 30646202
[TBL] [Abstract][Full Text] [Related]
19. Preoperative Nutrition Status and Postoperative Outcomes in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Reece L; Dragicevich H; Lewis C; Rothwell C; Fisher OM; Carey S; Alzahrani NA; Liauw W; Morris DL
Ann Surg Oncol; 2019 Aug; 26(8):2622-2630. PubMed ID: 31123932
[TBL] [Abstract][Full Text] [Related]
20. Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer.
Magge D; Ramalingam L; Shuai Y; Edwards RP; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL; Choudry HA
J Surg Oncol; 2017 Sep; 116(3):320-328. PubMed ID: 28628712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
